Epratuzumab-cys-SG3249

Drug Profile

Epratuzumab-cys-SG3249

Alternative Names: hLL2-cys-PBD

Latest Information Update: 24 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ADC Therapeutics
  • Class Antineoplastics; Benzodiazepines; Immunoconjugates; Monoclonal antibodies; Pyrroles
  • Mechanism of Action CD22 antigen inhibitors; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 03 Dec 2016 Preclinical trials in Haematological malignancies in Switzerland (SC)
  • 03 Dec 2016 Pharmacodynamics and adverse events data from a preclinical study in Haematological malignancies presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem - 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top